All News
Filter News
Found 35 articles
-
Biopharmaceuticals Contract Manufacturing Market is Banking on the Breakthrough Technological Innovations and Developments
8/12/2020
The outsourcing of biologics has seen a tremendous rise over the years prominently due to its benefits such as decreased investment in drug development and large-scale provision of manufacturing capabilities.
-
BioSpace Global Roundup, July 30
7/30/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for July 29, 2020.
-
BioSpace Global Roundup, June 25
6/25/2020
Biopharma and life sciences companies provide updates on their pipelines and business plans. -
BioSpace Global Roundup, June 11
6/11/2020
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses. -
Intravacc Partners With Wageningen Bioveterinary Research and Utrecht University to Develop an Intranasal COVID-19 Vaccine
6/4/2020
Intravacc, one of the world's leading translational research and development vaccine institutes, with an extensive track record in developing viral and bacterial vaccines, has announced more details on its development of an intranasal vaccine against COVID-19.
-
Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for June 2, 2020.
-
Intravacc and EpiVax Team up in Development of COVID-19 Emerging Vaccine
6/2/2020
Intravacc, one of the world's leading translational research and development vaccine institutes, with an extensive track record in developing viral and bacterial vaccines, and EpiVax, a biotechnology company based in Providence with expertise in developing vaccines and therapeutics
-
Intravacc and CDBIO sign a research and license agreement to further develop and commercialize a Meningococcal B vaccine
12/28/2018
Intravacc, a Dutch vaccine R&D institute in Bilthoven the Netherlands and CDBIO, a Chinese Biotech company in Shenyang, China todayannounce that they have signed a research and license agreement to further develop a vaccine against Meningococcal type B based on Intravacc’s proprietary Nonamen® vaccine technology.
-
Intravacc and BCHT enter into license agreement for production of a Hib conjugate vaccine
11/12/2018
Intravacc and Changchun BCHT Biotechnology Co today announced that they have entered into a non-exclusive license agreement towards the development ofa Haemophilus influenzae Type B (Hib) Conjugate Vaccine within the People’s Republic of China.
-
Sinovac Announces Preliminary Results of Phase III Trial on sIPV
4/19/2018
Sinovac Biotech Ltd. (NASDAQ: SVA) ("Sinovac " or the "Company"), a leading provider of biopharmaceutical products in China, today announced preliminary results of a phase III clinical study on Sabin inactivated polio vaccine ("sIPV") developed by Sinovac Biotech Co., Ltd. ("Sinovac Beijing") on the unblinding conference held on April 19, 2018.
-
Sinovac Biotech Ltd. Reports Unaudited Fourth Quarter And Full Year 2015 Financial Results
4/5/2016
-
Sinovac Biotech Ltd. Obtains Clinical Trial Approval For Sabin-IPV Candidate
12/10/2015
-
Sinovac Biotech Ltd. Enters Technology Transfer Agreement With Intravacc To Develop And Commercialize Sabin Inactivated Polio Vaccine (Sipv)
4/28/2014
-
Intravacc And Mylife Technologies Start Development Of Micro-Needle Vaccination To Break With Limitations Of Injected Vaccines
2/6/2014